Design Therapeutics, Inc. (DSGN)

↓ Download CSV

CIK 0001807120 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Design Therapeutics, Inc. reported revenue of $0. The company ran a net loss. It held $226.20M in total assets against $13.70M in total liabilities.

Key ratios (FY2025)

-32.8%
Return on equity
Metric (FY)2025202420232022202120202019
Revenue$0$0
Operating Income-$79.47M-$62.38M-$78.19M-$67.59M-$35.83M-$8.33M
Net Income-$69.79M-$49.59M-$66.86M-$63.31M-$35.53M-$8.28M
EPS (Diluted)$-1.22$-0.88$-1.19$-1.14$-0.77
Total Assets$226.20M$252.09M$289.64M$341.14M$390.56M$36.52M
Total Liabilities$13.70M$10.00M$11.96M$13.83M$8.43M$2.48M
Shareholders' Equity$212.50M$242.10M$277.69M$327.31M$382.13M-$11.31M-$3.64M
Cash & Equivalents$16.86M$22.56M$21.20M$26.50M$298.57M$2.38M
Operating Cash Flow-$54.36M-$43.10M-$58.56M-$51.32M-$29.38M-$8.67M
Capital Expenditures$193.0K$340.0K$256.0K$918.0K$1.54M$76.0K
Shares Outstanding60.40M56.75M56.47M55.90M55.44M15.96M